Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol

Annals of Clinical Microbiology and Antimicrobials

Volumn 13, Issue 1, 2014, Pages

  Abdulamir, Ahmed S ^a   Jassim, Sabah A A ^b   Abu Bakar, Fatimah ^c  

^a AL NAHRAIN UNIVERSITY   (Iraq)

^b Applied Bio Research Inc   (Canada)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Animal feed; Bacteriophage; Biocontrol; Bioprocessing; E. coli; Phage cocktail; Phage design

Indexed keywords

ALKALI; DRINKING WATER;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL SHEDDING; BACTERIAL STRAIN; BACTERIOPHAGE; BIOLOGICAL PEST CONTROL; BIOPROCESS; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROPATHOGENIC ESCHERICHIA COLI; FECES MICROFLORA; FEEDING; MICROCAPSULE; NONHUMAN; RAT; VEGETABLE; ANIMAL; BIOLOGICAL THERAPY; COLIPHAGE; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES; VIROLOGY;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL LOAD; BIOLOGICAL THERAPY; COLIPHAGES; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; RATS;

EID: 84906838435     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-014-0039-z     Document Type: Article

References (25)

1. Kaper JB, Nataro JP, Mobley HLT. Pathogenic Escherichia coli. Nat Rev Microbiol 2004, 2:123-140. 10.1038/nrmicro818, 15040260.
2. Carone BR, Xu T, Murphy KC, Marinus MG. High incidence of multiple antibiotic resistant cells in cultures of in enterohemorrhagic Escherichia coli O157:H7. Mutat Res 2014, 759:1-8. 10.1016/j.mrfmmm.2013.11.008.
3. Wall PG, McDonnell RJ, Adak GK, Cheasty T, Smith HR, Rowe B. General outbreaks of vero cytotoxin producing Escherichia coli O157 in England and Wales from 1992 to 1994. Commun Dis Rep CDR Rev 1996, 6:26-33.
4. Hawker J, Begg NB, Blair B, Reintjes R, Weinberg J. Communicable Disease Control Handbook 2001, Blackwell, Oxford.
5. Rasmussen MA, Casey TA. Environmental and food safety aspects of Escherichia coli O157:H7 infections in cattle. Crit Rev Microbiol 2001, 27:57-73. 10.1080/20014091096701, 11450854.
6. Hussein HS. Prevalence and pathogenicity of Shiga toxin-producing Escherichia coli in beef cattle and their products. J Anim Sci 2007, 85:E63-E72. 10.2527/jas.2006-421, 17060419.
7. Yoder JS, Blackburn BG, Craun GF, Hill V, Levy DA, Chen N, Lee SH, Calderon RL, Beach MJ. Surveillance for waterborne-disease outbreaks associated with recreational water-United States. MMWR Surveill Summ 2004, 53:1-22. 15499306.
8. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 2008, 197:1519-1522. 10.1086/587942, 18471063.
9. Rea MC, Alemayehu D, Ross RP, Hill C. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J Med Microbiol 2013, 62(Pt 9):1369-1378. 10.1099/jmm.0.058933-0, 23699066.
10. Merril CR, Scholl D, Adhya SL. The prospect for Bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2:489-497. 10.1038/nrd1111, 12776223.
11. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014, 5(1):226-235. 10.4161/viru.25991, 23973944.
12. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Genet 1997, 5:268-271.
13. Carlton RM. Phage therapy: past history and future prospects. Arch Immunol Ther Exp 1999, 47:267-274.
14. Verbeken G, Pirnay JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M, Huys I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp (Warsz) 2012, 60(3):161-172. 10.1007/s00005-012-0175-0.
15. Vieu JF. Les Bacteriophages. Fraite de Therapeutique 1975, 337-400. Vol. Serums et Vaccins. Flammarion, Paris, Fabre J.
16. Smith HW, Huggins MB. Effectiveness of phages in treatingexperimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983, 129:2659-2675. 6355391.
17. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987, 133:1111-1126. 3309177.
18. Tauxe RV. Emerging foodborne diseases: an evolving public health challenge. Emerg Infect Dis 1997, 3:425-434. 10.3201/eid0304.970403, 9366593.
19. Topley WWC, Wilson GS. Principles of bacteriology, virology and immunity 1990, B.C. Decker Publisher, London, United Kingdom.
20. Drake D. Assessment of antimicrobial activity against biofilms. Microbial growth in biofilms vol. 2 2001, 373-375. Academic press, London, UK, Doyle RJ.
21. Garber L, Wells S, Shroeder-tucker L. Factors associated with the faecal shedding of verotoxin-producing Escherichia coli O157 on dairy farms. J Food Prot 1999, 62:307-312. 10419200.
22. Callaway TR, Anderson RC, Edrington TS, Genovese KJ, Bischoff KM, Poole TL, Jung YS, Harvey RB, Nisbet DJ. What are we doing about Escherichia coli O157:H7 in cattle?. J Anim Sci 2004, 82(E-Suppl):E93-E99. 15471819.
23. Duckworth DH, Gulig PA. Bacteriophages: potential treatment for bacterial infections. BioDrugs 2002, 16:57-62. 10.2165/00063030-200216010-00006, 11909002.
24. Chibeu A, Agius L, Gao A, Sabour PM, Kropinski AM, Balamurugan S. Efficacy of bacteriophage LISTEXP100 combined with chemical antimicrobials in reducing Listeria monocytogenes in cooked turkey and roast beef. Int J Food Microbiol 2013, 167(2):208-214. 10.1016/j.ijfoodmicro.2013.08.018, 24125778.
25. Drilling A, Morales S, Boase S, Jervis-Bardy J, James C, Jardeleza C, Tan NC, Cleland E, Speck P, Vreugde S, Wormald PJ. Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. Int Forum Allergy Rhinol 2014, 4(3):176-186. 10.1002/alr.21270, 24449635.